BioSpring GmbH’s Post

📢 Attention, time change! May 16th, at 14:40, Stage 5    ✅ "From risk to remedy – Polish biotech's answers to sustain stable drug and diagnostics supply during shortages"  🎤 Join the discussion panel at Impact CEE, where Konstantin Matentzoglu (Polpharma Biologics) alongside Katarzyna Rolle (Polish Academy of Sciences), Dariusz Adamusiński (MedTech Poland), and moderator Joanna Bekker (Polityka Insight) will discuss how collaboration between businesses and science can strengthen supply chains when needed. Don't miss this important discussion! #IMPACTCEE #Innovation #Biotechnology #PolpharmaBiologics

Drug-Linker manufacturing and ADC conjugation facilities require specific regulatory knowledge and an engrained safety culture. They also bring their own unique design, construction and operational challenges. My presentation at INTERPHEX Global has generated some really great conversations about the future of this modality and how we plan to push towards that future. Let's keep the discussion going - what are your biggest challenges when designing and operating these complex facilities? #CRB #ADC #AntibodyDrugConjugate

Come learn about increasing productivity and reducing cost for large-scale LVV production!

With our recent partnered licensing agreement news with Synthego Corporation on the next-generation CRISPR high-fidelity Cas12Max (hfCas12Max) nuclease, it all started with a casual colleague-colleague conversation. Are you looking to collaborate? Our CEO, Alvin Luk, and Sr. Director of International Business Development, Xixi Zhu, will be at #BIO2024 , organized by the Biotechnology Innovation Organization, June 3-6, to discuss how, together, we can bring transformative therapies to patients worldwide. Don't get to schedule a 1on1 discussion with Xixi Zhu. #genetherapy #geneediting #CRISPR #genomemedicine #biotechnology #innovation #medicine #pharmaceuticals #licensing #licensingagreement #opportunities #partnerships #collaboration #accessibility #health #scienceandtechnology #technology #healthcare #science #research

Check out the latest episode of The BioCentury Show with new BIO (Biotechnology Innovation Organization) President & CEO John F. Crowley. ✅ Watch: https://lnkd.in/d-Fr_KRD John speaks with my BioCentury Inc. colleague Steve Usdin about several topics, including: ➢ Why BIO's position on the #Biosecure Act and WuXi AppTec and WuXi Biologics has changed. ➢ Why FDA should create a rare diseases center of excellence. ➢ Why BIO is planning "fly out" visits to cities around the U.S. ➢ Where common ground can be found between the biotech industry and Capitol Hill. ➢ How BIO plans to demonstrate the unintended consequences of the #IRA on drug development. And much more.... Watch or listen on YouTube. #biotech #biopharma #drugdevelopment #drugpricing #decoupling

Irrespective of the NGS Platform you are working on, if you have a pipetting intensive Magnetic Bead based Size selection and/or Clean-up step, please let us make your work much easier with the CyBio Felix. The video highlights the ease with reliability and reproducibility associated with automation, #FlexYourFeliX, me thinks 😎

🔬Today, let’s start the Wednesday with #DeliveringScience: Advancing Safe Drug Delivery with LNPs 💡 At Certest Pharma, we recognize the critical importance of toxicity studies when developing new formulations of Lipid Nanoparticles (LNPs) and ionizable lipids. Our proprietary, thermally stable LNPs undergo rigorous toxicity assessments to ensure the highest standards of safety and efficacy. In our in vivo safety profile study, we analyzed key biomarkers such as AST, ALT, ALP, urea, and albumin to evaluate potential toxicity. 👉🏻The results? Our formulations demonstrated comparable performance to the Gold Standard, confirming the safety of our innovative approach to drug delivery. With every study, we continue to push the boundaries of what’s possible in precision medicine, delivering safe and effective solutions for the future of healthcare. 📩 Have questions about our toxicity studies? Don’t hesitate to contact us at pharma@certest.es. #LNPs #IonizableLipids #ToxicityStudies #InVivo #DrugDelivery #Biotech #PharmaInnovation #CertestPharma

Patient-derived cells (PDCs): the future of drug discovery Drug discovery is known for its high attrition rates that lead to significant investments in both cost and time. However, the emergence of patient-derived cells (PDCs) is on track to revolutionise this process, offering a promising route to more efficient and effective drug development. In this blog, the Inaphaea team explores the potential of PDCs and their role in shaping the future of drug discovery. Read the blog here: https://bit.ly/43gvTcL #Assays #AssayDevelopment #BioTech #DrugDiscovery #CancerResearch #ScientificResearch #PDCs

Novelty for those of us pursuing new therapeutic agents within the specialized drug discovery domain extends far beyond what is merely new. It demands both innovation and practical applicability. Here's our take on the challenge of novelty in drug discovery. #drugdiscovery #biopharma #drugresearch #innovation #seeIPdifferently #biotech #drugresearch https://lnkd.in/etXdjbtZ

It is a beautiful day in San Diego, looking forward to meeting many of the drug discovery experts at #DDC this week, or at the Viva Biotech reception, to discuss and share some of the most exciting developments in drug discovery, especially for challenging #drugtargets and #modalities, both in our industry and at Viva (https://lnkd.in/guXgZhsn). #DEL #ASMS #SPR #CryoEM #CADD #AIDD #SBDD #FBDD #Medchem #Bioassay #AntibodyDiscovery #ADME #PK #TPD #XDC #Peptide #Neucleotide #LeadDiscovery #HTS #Covalent #PeptideMapping #IntactMS #NativeMS, #HDX, #Crystallography #CrystalSoaking #PhageDisplay #Nanobody #MammalianDisplay #ProteinScience #ProcessChemistry #API #Formulation #CMC #GMP